400 new jobs at Regeneron ‘a huge boost’ to the Mid-West

400 new jobs are to be created by Regeneron Pharmaceuticals, Inc in the Mid-West.

More than 1,400 people will now be employed at Regeneron’s industrial operations and product supply campus in Limerick which already counts several Clare residents among its workforce.

Recruitment to hire full-time, high-end specialist jobs in commercial manufacturing, process sciences, quality assurance/control, supply chain and various support functions for scientists, chemists and technicians is underway.

Since 2014, more than $1bn has been invested by the biopharmaceutical company to build the largest bulk biologics production facility in the country. Presently, there are over 1,000 employees, more than 300 contingent workers and close to 500 construction personnel on the site.

“As this pandemic hit, we needed to quickly change how we do things and where we make our products. In order to make space in our New York facilities to accommodate our COVID-19 efforts, we needed to ramp-up capacity here in Limerick. Despite ramping up commercial production sooner than planned, my team hasn’t missed a beat. You can only perform like this if you have good people, and Ireland has lots of good people, so we are excited to be hiring 400 more,” Dan Van Plew, Executive Vice President & General Manager of IOPS at Regeneron stated.

Site Head at the Raheen Business Park campus, Niall O’Leary believed the announcement demonstrated the company’s “incredibly strong pipeline” and a “commitment to Ireland and the Mid-West region”.

Executive Director with IDA Ireland, Mary Buckley noted that the addition of 400 jobs was a timely lift to the region. “The addition of 400 highly skilled roles by Regeneron at its Limerick campus is a huge boost for Ireland and the Mid-West region. The company has expanded rapidly since it first chose to locate in Limerick. This significant job announcement by Regeneron in a regional location is very welcome and points to Ireland’s reputation as a global location of excellence for biopharmaceuticals”.